Yuichi Sugiyama

Q: What Schools Are Affiliated With Yuichi Sugiyama

Yuichi Sugiyama is affiliated with the following schools: Shizuoka University, University of Tokyo, Riken, Kyoto University

Yuichi Sugiyama's AcademicInfluence.com Rankings

Yuichi Sugiyama

Computer Science

#3162

World Rank

#3313

Historical Rank

Algorithms

#81

World Rank

#81

Historical Rank

Computational Linguistics

#121

World Rank

#124

Historical Rank

Machine Learning

#309

World Rank

#313

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Yuichi Sugiyama's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Yuichi Sugiyama Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yuichi Sugiyama's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Membrane transporters in drug development (2010) (2882)
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013) (1068)
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. (2006) (560)
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. (2003) (554)
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. (1998) (518)
Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics (2003) (506)
Transporters as a determinant of drug clearance and tissue distribution. (2006) (489)
Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain* (1999) (483)
Impact of Drug Transporter Studies on Drug Discovery and Development (2003) (481)
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. (1997) (464)
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans (2004) (449)
Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin (2002) (436)
Molecular Cloning and Characterization of Multispecific Organic Anion Transporter 4 Expressed in the Placenta* (2000) (394)
Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. (2001) (390)
Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil (2004) (385)
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. (2013) (354)
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin (2008) (354)
ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* (2003) (350)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans (2009) (347)
Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A (2003) (344)
Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. (2005) (338)
Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. (2001) (302)
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 (2006) (294)
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. (1998) (294)
Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. (1997) (292)
Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. (2000) (289)
Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir (2007) (286)
Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. (1998) (277)
Functional Characterization of Rat Brain-specific Organic Anion Transporter (Oatp14) at the Blood-Brain Barrier (2003) (277)
FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA (2005) (276)
Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. (2003) (270)
Functional Analysis of SNPs Variants of BCRP/ABCG2 (2004) (270)
Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone (2010) (259)
Characterization of inducible nature of MRP3 in rat liver. (2000) (253)
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin (2005) (250)
Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* (2002) (239)
Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. (1996) (237)
In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. (2009) (225)
Characterization of uremic toxin transport by organic anion transporters in the kidney. (2004) (218)
Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver (2013) (215)
Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. (2002) (215)
Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens (2007) (207)
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs (2009) (204)
Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). (2000) (202)
Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects (2011) (201)
Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein (2001) (199)
Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development (2009) (196)
Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans (2010) (195)
INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS (2006) (195)
CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS (2005) (193)
cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3) 1 (1998) (193)
Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study (2011) (192)
Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R (2005) (190)
Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. (1997) (190)
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (2006) (190)
Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. (2003) (187)
Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney (2012) (185)
Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. (2001) (185)
Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. (2003) (184)
Active efflux across the blood-brain barrier: Role of the solute carrier family (2011) (181)
Characterization of the Efflux Transport of 17β-Estradiol-d-17β-glucuronide from the Brain across the Blood-Brain Barrier (2001) (179)
Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. (1997) (174)
Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport (2005) (173)
Cisplatin-Loaded Polymer-Metal Complex Micelle with Time-Modulated Decaying Property as a Novel Drug Delivery System (2001) (172)
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. (2008) (171)
Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. (2002) (171)
PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS (2006) (171)
Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. (2002) (169)
Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. (1993) (166)
A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters (2005) (166)
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin (2005) (163)
4‐phenylbutyrate enhances the cell surface expression and the transport capacity of wild‐type and mutated bile salt export pumps (2007) (159)
Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. (2004) (157)
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). (2004) (154)
SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers (2007) (153)
P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. (1997) (153)
ATP-binding cassette, subfamily G (ABCG family) (2007) (153)
Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. (1998) (151)
Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. (2000) (148)
Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies (2012) (146)
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. (2002) (144)
Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds (2008) (144)
Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. (2002) (142)
Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices (2007) (142)
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. (1997) (142)
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. (2004) (141)
Potent and Specific Inhibition of mMate1-Mediated Efflux of Type I Organic Cations in the Liver and Kidney by Pyrimethamine (2010) (138)
Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor (2007) (138)
Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs (2006) (137)
Functional Characterization of Mouse Organic Anion Transporting Peptide 1a4 in the Uptake and Efflux of Drugs Across the Blood-Brain Barrier (2010) (136)
Recent Advances in Carrier-mediated Hepatic Uptake and Biliary Excretion of Xenobiotics (1996) (133)
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia (2008) (132)
Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver (2000) (128)
Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Res (2009) (127)
Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein (2005) (127)
Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. (2003) (127)
Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP (2012) (125)
Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions (2015) (122)
P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION (2005) (122)
Transport Activity of Human MRP3 Expressed in Sf9 Cells: Comparative Studies with Rat MRP3 (2004) (121)
Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. (2012) (120)
Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. (2013) (117)
Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach (1999) (116)
The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. (1998) (116)
Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport (2002) (114)
Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). (2001) (114)
Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. (1997) (114)
Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). (2001) (114)
The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine (2009) (113)
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium (2018) (113)
Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier (2003) (112)
Functional Analysis of a Canalicular Multispecific Organic Anion Transporter Cloned from Rat Liver* (1998) (112)
A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. (2003) (111)
Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans (2010) (111)
Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. (2007) (110)
The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling (2008) (110)
Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate (2011) (110)
Importance of the liver in plasma clearance of hepatocyte growth factors in rats. (1992) (110)
Efflux transport systems for organic anions and cations at the blood-CSF barrier. (2004) (107)
Effect of excipients on breast cancer resistance protein substrate uptake activity. (2007) (106)
Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. (1998) (106)
REGULATION OF THE CELL SURFACE EXPRESSION OF HUMAN BCRP/ABCG2 BY THE PHOSPHORYLATION STATE OF AKT IN POLARIZED CELLS (2005) (105)
Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 (2004) (105)
Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. (2004) (103)
Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients (2007) (103)
Prediction of Fluoroquinolone‐Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion (2011) (103)
Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. (1998) (102)
In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. (1997) (102)
Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. (1993) (102)
Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11 (2005) (102)
cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). (1998) (100)
Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose (2012) (99)
Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine (2008) (99)
Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices (2007) (98)
Contribution of Organic Anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat (2003) (98)
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. (2002) (98)
Genipin enhances Mrp2 (Abcc2)‐mediated bile formation and organic anion transport in rat liver (2004) (96)
Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. (2005) (94)
Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 (2000) (94)
Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments (2011) (94)
Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones (2007) (94)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation (2012) (93)
Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers (2006) (93)
Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. (2002) (93)
Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). (1997) (92)
PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me (2012) (91)
Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. (2001) (91)
The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. (2003) (90)
Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. (2006) (89)
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. (2001) (89)
Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. (1998) (89)
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. (1999) (88)
P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier (2008) (88)
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches (2018) (88)
Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. (1996) (88)
Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system☆ (1997) (88)
Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates (2010) (87)
Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. (2000) (87)
Newly identified bile acid binders in rat liver cytosol. Purification and comparison with glutathione S-transferases. (1983) (86)
Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans (2008) (85)
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013) (84)
Quantitative Evaluation of the Function of Small Intestinal P-Glycoprotein: Comparative Studies Between in Situ and in Vitro (2003) (84)
Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein. (1999) (83)
Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein (2013) (83)
In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil (2006) (83)
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium (2018) (83)
Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. (1999) (83)
N‐Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2‐K) (2012) (83)
Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. (2002) (83)
Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method (2016) (82)
Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen (2005) (81)
Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes (2011) (81)
A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU (2001) (80)
The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function (2001) (80)
Prediction of the volumes of distribution of basic drugs in humans based on data from animals (1984) (80)
Regulation of the Expression of Human Organic Anion Transporter 3 by Hepatocyte Nuclear Factor 1α/β and DNA Methylation (2006) (80)
Involvement of MRP4 (ABCC4) in the Luminal Efflux of Ceftizoxime and Cefazolin in the Kidney (2007) (80)
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? (2002) (79)
Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. (2004) (79)
Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide (2008) (79)
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. (1998) (79)
Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier (2004) (79)
Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. (2007) (78)
In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models (1982) (77)
Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. (2007) (77)
Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. (1998) (76)
Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. (2012) (75)
The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. (2005) (75)
Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. (1998) (75)
Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. (1999) (75)
Molecular Cloning and Functional Analyses of OAT1 and OAT3 from Cynomolgus Monkey Kidney (2005) (74)
Species differences in the transport activity for organic anions across the bile canalicular membrane. (1999) (74)
Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism (2013) (74)
Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. (1999) (74)
Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. (2014) (74)
Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2 (1999) (73)
Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). (2006) (73)
Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments (2009) (73)
Endogenous Probes for Drug Transporters: Balancing Vision With Reality (2018) (73)
Prediction of the disposition ofβ-lactam antibiotics in humans from pharmacokinetic parameters in animals (1984) (72)
Multiple transport systems for organic anions across the bile canalicular membrane. (1994) (72)
Involvement of Multidrug Resistance Associated Protein 1 (Mrp1) in the Efflux Transport of 17β Estradiol-D-17β-Glucuronide (E217βG) Across the Blood-Brain Barrier (2003) (72)
In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans (2001) (72)
Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. (2011) (71)
Gender Difference in the Urinary Excretion of Organic Anions in Rats (2002) (70)
Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. (2006) (70)
Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. (2000) (69)
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. (2001) (69)
Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. (2004) (68)
Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model (1983) (68)
Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters (2010) (68)
Reduced Gastrointestinal Toxicity Following Inhibition of the Biliary Excretion of Irinotecan and Its Metabolites by Probenecid in Rats (2002) (68)
Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats (1985) (68)
Drug transporters: their role and importance in the selection and development of new drugs. (2002) (67)
Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. (1998) (67)
Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. (2000) (67)
INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID (2006) (67)
Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. (1997) (66)
Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations (2019) (66)
Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. (2001) (66)
Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the brain efflux index method. (1997) (64)
Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs (2004) (64)
Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers (2018) (64)
Regional Expression and Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Mouse Intestine: Overlapping Distribution with Sulfotransferases (2007) (63)
Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. (2014) (62)
Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats (1996) (62)
Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. (2002) (61)
Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) (2008) (61)
Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride–intoxicated rats (1993) (61)
Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. (2003) (61)
Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. (1989) (60)
Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi (2001) (60)
Regulation of Tissue-Specific Expression of the Human and Mouse Urate Transporter 1 Gene by Hepatocyte Nuclear Factor 1 α/β and DNA Methylation (2007) (59)
Transcriptional Regulation of Human and Mouse Organic Anion Transporter 1 by Hepatocyte Nuclear Factor 1 α/β (2008) (59)
3 alpha-hydroxysteroid dehydrogenase activity of the Y' bile acid binders in rat liver cytosol. Identification, kinetics, and physiologic significance. (1987) (59)
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development (2016) (59)
Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. (2013) (59)
Impact of microdosing clinical study -- why necessary and how useful? (2011) (59)
Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats (2009) (59)
Human placental extract stimulates liver regeneration in rats. (1998) (58)
The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. (2004) (58)
Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. (1994) (58)
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. (2003) (58)
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. (2005) (58)
Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. (1995) (58)
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein (2009) (57)
Analysis of Nonlinear and Nonsteady State Hepatic Extraction with the Dispersion Model Using the Finite Difference Method (1998) (57)
Involvement of carrier-mediated transport system in uptake of tetrodotoxin into liver tissue slices of puffer fish Takifugu rubripes. (2007) (56)
The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model (2018) (56)
Short-Chain Ubiquitination Is Associated with the Degradation Rate of a Cell-Surface-Resident Bile Salt Export Pump (BSEP/ABCB11) (2009) (55)
The Eighth and Ninth Transmembrane Domains in Organic Anion Transporting Polypeptide 1B1 Affect the Transport Kinetics of Estrone-3-Sulfate and Estradiol-17β-D-glucuronide (2009) (55)
Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. (1997) (55)
Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases (1988) (55)
Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. (1997) (55)
Biliary Excretion of 17β-Estradiol 17β-d-Glucuronide Is Predominantly Mediated by cMOAT/MRP2 (2000) (55)
Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. (2001) (55)
Sinusoidal Efflux of Taurocholate Is Enhanced in Mrp2-Deficient Rat Liver (2001) (55)
Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. (1997) (55)
Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. (1999) (54)
Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. (2000) (54)
Transporters for bile acids and organic anions. (1999) (53)
The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. (2011) (53)
The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers (2011) (53)
Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats (2013) (53)
Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists (2006) (53)
Inhibition of In Vitro Metabolism of Simvastatin by Itraconazole in Humans and Prediction of In Vivo Drug-Drug Interactions (2001) (53)
Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. (2010) (53)
Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. (2012) (53)
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers (2017) (52)
Delays in New Drug Applications in Japan and Industrial R&D Strategies (2010) (52)
Multiple systems for the biliary excretion of organic anions in rats: liquiritigenin conjugates as model compounds. (1994) (52)
Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product (2004) (52)
Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one) (2007) (51)
Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant (1982) (51)
AP2 adaptor complex mediates bile salt export pump internalization and modulates its hepatocanalicular expression and transport function (2012) (51)
Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4 (1999) (51)
Preincubation‐dependent and long‐lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug‐drug interactions (2017) (51)
Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. (1999) (51)
Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide. (1997) (51)
Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate. (2001) (50)
Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. (1997) (50)
Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs (2020) (50)
Primary active transport of organic anions on bile canalicular membrane in humans. (1999) (50)
Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. (2004) (49)
Expression and transport function of drug uptake transporters in differentiated HepaRG cells. (2012) (49)
Differential Involvement of Multidrug Resistance-Associated Protein 1 and P-Glycoprotein in Tissue Distribution and Excretion of Grepafloxacin in Mice (2004) (49)
Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. (2003) (49)
Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose (2011) (49)
Identification of annexin A1 as a novel substrate for E6AP‐mediated ubiquitylation (2009) (49)
Novel strategies for microdose studies using non-radiolabeled compounds. (2011) (48)
Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases. (2002) (48)
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. (2004) (48)
Multidrug resistance-associated protein2 (MRP2) plays an important role in the biliary excretion of glutathione conjugates of 4-hydroxynonenal. (2002) (47)
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect (2007) (47)
Characterization of Polarized Expression of Point- or Deletion-Mutated Human BCRP/ABCG2 in LLC-PK1 Cells (2005) (47)
Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir (2011) (47)
Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. (2006) (46)
Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins (2013) (46)
Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro as well as on physiological data (1982) (46)
Ezrin and radixin both regulate the apical membrane localization of ABCC2 (MRP2) in human intestinal epithelial Caco-2 cells. (2007) (46)
Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information (2016) (46)
Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. (1997) (46)
Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data (2009) (46)
Analysis of DNA Methylation and Histone Modification Profiles of Liver-Specific Transporters (2009) (46)
Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study (2011) (45)
Effect of 17β-Estradiol-d-17β-Glucuronide on the Rat Organic Anion Transporting Polypeptide 2-Mediated Transport Differs Depending on Substrates (2002) (45)
Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information (2013) (45)
Organic Anion Transporter 3 Mediates the Efflux Transport of an Amphipathic Organic Anion, Dehydroepiandrosterone Sulfate, across the Blood-Brain Barrier in Mice (2011) (45)
Investigation of Endogenous Compounds Applicable to Drug–Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans (2016) (45)
Glutathione S-transferases in elasmobranch liver. Molecular heterogeneity, catalytic and binding properties, and purification. (1981) (44)
6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects (2014) (44)
Positron Emission Tomography Studies Using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport (2010) (44)
Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines (2013) (43)
A novel skeletal drug delivery system using self-setting calcium phosphate cement VIII: the relationship between in vitro and in vivo drug release from indomethacin-containing cement (1997) (43)
Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. (2002) (43)
Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. (2000) (43)
Drug interaction between simvastatin and itraconazole in male and female rats. (2001) (42)
Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values (2012) (42)
Kinetic Analysis of Hepatobiliary Transport for Conjugated Metabolites in the Perfused Liver of Mutant Rats (EHBR) with Hereditary Conjugated Hyperbilirubinemia (1995) (42)
Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. (2007) (42)
Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. (2012) (42)
Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. (2000) (42)
Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. (1999) (42)
High-affinity efflux transport system for glutathione conjugates on the luminal membrane of a mouse brain capillary endothelial cell line (MBEC4). (1999) (42)
Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. (2006) (42)
Microdose Study of 14C‐Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects (2010) (41)
Reduced folate derivatives are endogenous substrates for cMOAT in rats. (1998) (41)
Receptor-Mediated Transport of Peptide Hormones and Its Importance in the Overall Hormone Disposition in the Body (1989) (41)
Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. (1995) (41)
The antipsychotic sultopride is overdosed--a PET study of drug-induced receptor occupancy in comparison with sulpiride. (2006) (40)
Evaluation of the Uptake of Pravastatin by Perfused Rat Liver and Primary Cultured Rat Hepatocytes (1995) (40)
Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. (1998) (40)
Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. (2013) (40)
PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3 (2018) (40)
Construction of Triple-Transfected Cells [Organic Anion-Transporting Polypeptide (OATP) 1B1/Multidrug Resistance-Associated Protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for Analysis of the Sinusoidal Function of MRP3 and MRP4 (2009) (40)
In Vivo Biliary Clearance Should Be Predicted by Intrinsic Biliary Clearance in Sandwich-Cultured Hepatocytes (2012) (40)
Expression and Functional Involvement of Organic Anion Transporting Polypeptide Subtype 3 (Slc21a7) in Rat Choroid Plexus (2003) (39)
Regulation of Tissue-Specific Expression of Renal Organic Anion Transporters by Hepatocyte Nuclear Factor 1 α/β and DNA Methylation (2012) (39)
Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. (2017) (39)
Expression of a putative ATP-binding cassette region, homologous to that in multidrug resistance-associated protein (MRP), is hereditarily defective in Eisai hyperbilirubinemic rats (EHBR) (1996) (39)
Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins (2017) (39)
Feature Extraction and Summarization of Recipes Using Flow Graph (2013) (39)
Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays. (2016) (39)
Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. (2019) (39)
Comparison between in‐vivo and in‐vitro tissue‐to‐plasma unbound concentration ratios (Kp,f) of quinidine in rats (1984) (39)
Characterization of 5'-flanking region of human MRP3. (2000) (39)
Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance–Associated Protein 2 Using Ligand-Based Drug Design Techniques (2005) (38)
Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes (2013) (38)
In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. (2004) (38)
Binding of bile acids by glutathione S-transferases from rat liver. (1986) (38)
Transporter biology in drug approval: regulatory aspects. (2013) (38)
Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse (2015) (38)
Ubiquitination is associated with lysosomal degradation of cell surface‐resident ATP‐binding cassette transporter A1 (ABCA1) through the endosomal sorting complex required for transport (ESCRT) pathway (2011) (37)
Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807 (2013) (37)
DNA Methylation Profiles of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines (2010) (37)
Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects (2013) (37)
Construction of a Functional Transporter Analysis System Using MDR1 Knockdown Caco-2 Cells (2005) (37)
Effect of geometrical cement size on in vitro and in vivo indomethacin release from self-setting apatite cement. (1998) (37)
Pharmacokinetic Study of the Hepatobiliary Transport of Indomethacin (2000) (37)
A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug. (2000) (37)
The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. (2013) (36)
Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs. (1996) (36)
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism (2008) (36)
Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier (2004) (36)
The ATP-Binding Cassette Transporter BCRP1/ABCG2 Plays a Pivotal Role in Cardiac Repair After Myocardial Infarction Via Modulation of Microvascular Endothelial Cell Survival and Function (2010) (36)
Do multidrug resistance-associated protein-1 and -2 play any role in the elimination of estradiol-17 beta-glucuronide and 2,4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier? (2004) (36)
Identification and purification of a 36 kDa bile acid binder in human hepatic cytosol (1984) (35)
In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters (2010) (35)
Specific renal delivery of sugar-modified low-molecular-weight peptides. (1999) (35)
Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2– Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration (2015) (35)
The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. (2001) (35)
Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. (1996) (35)
Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. (2008) (35)
Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches. (2017) (35)
Renal drug targeting using a vector "alkylglycoside". (1999) (34)
Sorting Nexin 27 Interacts with Multidrug Resistance-associated Protein 4 (MRP4) and Mediates Internalization of MRP4* (2012) (34)
Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis. (1997) (34)
Genome-wide analysis of epigenetic signatures for kidney-specific transporters. (2010) (34)
A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling (2009) (33)
Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics (1985) (33)
HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154 (2004) (33)
Triple hydrogen bonds direct crystal engineering of metal-assembled complexes: the effect of a novel organic-inorganic module on supramolecular structure. (2005) (33)
Imaging of Gastrointestinal Absorption and Biodistribution of an Orally Administered Probe Using Positron Emission Tomography in Humans (2012) (33)
A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography (2018) (33)
Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS (2010) (32)
Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. (2003) (32)
Contribution of OATP 2 ( OATP 1 B 1 ) and OATP 8 ( OATP 1 B 3 ) to the Hepatic Uptake of Pitavastatin in Humans (2004) (32)
Comparison of the Hepatic Uptake Clearances of Fifteen Drugs with a Wide Range of Membrane Permeabilities in Isolated Rat Hepatocytes and Perfused Rat Livers (1993) (32)
The use of hepatocytes to investigate drug uptake transporters. (2010) (31)
Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. (2010) (31)
Involvement of Different Human Glutathione Transferase Isoforms in the Glutathione Conjugation of Reactive Metabolites of Troglitazone (2011) (31)
Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans (2008) (31)
Physiologically based pharmacokinetics of drug-drug interaction: A study of tolbutamide-sulfonamide interaction in rats (1982) (31)
Phase 0/microdosing approaches: time for mainstream application in drug development? (2020) (31)
Importance of hepatic first-pass removal in metastasis of colon carcinoma cells. (1998) (31)
Evidence for a common high affinity binding site on glutathione S-transferase B for lithocholic acid and bilirubin. (1984) (30)
pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. (2002) (30)
Expression and regulation of breast cancer resistance protein and multidrug resistance associated protein 2 in BALB/c mice. (2006) (30)
Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method (1985) (30)
Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications (2020) (30)
Design of a drug delivery system for targeting based on pharmacokinetic consideration (1996) (30)
Auramine O as a fluorescent probe for the binding of basic drugs to human α1-acid glycoprotein (α1-AG): the development of a simple fluorometric method for the determination of α1-AG in human serum (1985) (30)
Human Organic Anion Transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) Transport Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and Its Sulfate Conjugate (2007) (30)
Heparin‐hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity (1994) (30)
4-Phenylbutyrate modulates ubiquitination of hepatocanalicular MRP2 and reduces serum total bilirubin concentration. (2012) (30)
Relationship between the newly identified bile acid binder and bile acid oxidoreductases in human liver. (1990) (30)
Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital, and thiopental in the rat (1982) (29)
Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. (2018) (29)
Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs (2013) (29)
Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients. (2009) (29)
Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. (2002) (29)
Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: an analysis based on metabolite kinetics. (1993) (29)
Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects (2018) (29)
Dynamic analysis of fluid distribution in the gastrointestinal tract in rats: positron emission tomography imaging after oral administration of nonabsorbable marker, [(18)F]Deoxyfluoropoly(ethylene glycol). (2013) (29)
Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. (1995) (28)
Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2) (2005) (28)
A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions (2017) (28)
Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. (1995) (28)
Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. (1994) (28)
Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects (1996) (28)
Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation. (2011) (28)
Basolateral Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) Facilitates Intestinal Absorption of Folates in Mouse (2010) (27)
Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. (2000) (27)
Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. (2009) (27)
Carrier-mediated hepatic uptake of the cationic cyclopeptide, octreotide, in rats. Comparison between in vivo and in vitro. (1997) (27)
The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model (2016) (27)
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1. (2011) (27)
Different relationships between cellular ATP and hepatic uptake among taurocholate, cholate, and organic anions. (1993) (27)
Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat liver (1988) (27)
Toxicological implications of hepatobiliary transporters. (2002) (26)
Druggability: selecting optimized drug candidates. (2005) (26)
Effects of potential damaging agents on the microclimate-pH in the rat jejunum. (1986) (26)
Species difference in nisoldipine oxidation activity in the small intestine. (2002) (26)
Newly identified organic anion-binding proteins in rat liver cytosol. (1982) (26)
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP 1 B 1 (2006) (26)
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. (2004) (26)
Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3 (2008) (26)
Functional Characterization of Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) in the Basolateral Efflux of Glucuronide Conjugates in the Mouse Small Intestine (2010) (26)
Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. (2003) (25)
Characterization of novel kidney-specific delivery system using an alkylglucoside vector. (2001) (25)
Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery system (1996) (25)
Investigation of 5‐FU disposition after oral administration of capecitabine, a triple‐prodrug of 5‐FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5‐FU exposures in the tumour tissue between human and xenograft model (2001) (25)
ATP-dependent transport of organic anions into isolated basolateral membrane vesicles from rat intestine. (2004) (25)
Synthesis of [(11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. (2012) (24)
Physiological Modeling of Altered Pharmacokinetics of a Novel Anticancer Drug, UCN-01 (7-Hydroxystaurosporine), Caused by Slow Dissociation of UCN-01 from Human α1-Acid Glycoprotein (2000) (24)
Comparison of the affinities of newly identified human bile acid binder and cationic glutathione S-transferase for bile acids. (1986) (24)
Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor, Resulting in a Hypocholesterolemic Action (2007) (24)
In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. (2002) (24)
In‐vivo and In‐vitro Evidence of a Carrier‐mediated Efflux Transport System for Oestrone‐3‐sulphate across the Blood‐Cerebrospinal Fluid Barrier (2000) (24)
Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics. (1995) (24)
Pharmacokinetics and mechanism of intestinal absorption of JBP485 in rats. (2010) (24)
Effect of the Fluoroquinolone Antibacterial Agent DX-619 on the Apparent Formation and Renal Clearances of 6β-Hydroxycortisol, an Endogenous Probe for CYP3A4 Inhibition, in Healthy Subjects (2013) (24)
Drug-Drug Interactions Involving the Membrane Transport Process (2001) (24)
Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells. (1998) (24)
Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier. (2017) (23)
Calreticulin facilitates the cell surface expression of ABCG5/G8. (2006) (23)
Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms (2009) (23)
Oestradiol Release from Self‐setting Apatitic Bone Cement Responsive to Plasma‐calcium Level in Ovariectomized Rats, and its Physicochemical Mechanism (1997) (23)
Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. (2013) (23)
Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4 (2011) (23)
Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. (2002) (23)
Subunit interaction in unadenylylated glutamine synthetase from Escherichia coli. Evidence from methionine sulfoximine inhibition studies. (1981) (22)
Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates. (2015) (22)
DNA Methylation and Histone Modification Profiles of Mouse Organic Anion Transporting Polypeptides (2013) (22)
R 2 MEMBRANE TRANSPORTERS AND DRUG RESPONSE (2005) (22)
Transporters in Drug Development (2013) (21)
Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies (2008) (21)
Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. (1996) (21)
Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. (2001) (21)
Comparison of the binding affinities of five forms of rat glutathione S-transferases for bilirubin, sulfobromophthalein and hematin. (1984) (21)
Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. (1997) (21)
Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. (2014) (21)
Decreased Hepatic Breast Cancer Resistance Protein Expression and Function in Multidrug Resistance-Associated Protein 2-Deficient (TR−) Rats (2011) (21)
Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. (1998) (21)
In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase‐nonspecific agents under the clinically equivalent area under the curve (1992) (21)
Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. (2000) (21)
Marked Strain Differences in the Pharmacokinetics of an α4β1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism (2007) (21)
FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN (2005) (21)
In Silico Prediction of Major Drug Clearance Pathways by Support Vector Machines with Feature-Selected Descriptors (2014) (21)
Effective use of microdosing and Positron Emission Tomography (PET) studies on new drug discovery and development. (2009) (21)
Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: Analysis by multiple indicator dilution method (1986) (21)
Biliary Excretion of Glycyrrhizin in Rats: Kinetic Basis for Multiplicity in Bile Canalicular Transport of Organic Anions (1996) (21)
Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. (2002) (21)
Crystal engineering using the versatility of 2,5-dichloro-3,6-dihydroxy-1,4-benzoquinone with organic and metal complex partners (2003) (21)
A novel binding site for bile acids on human serum albumin. (1987) (21)
Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. (1998) (20)
Analysis of the success rates of new drug development in Japan and the lag behind the US. (2012) (20)
Rapid Elimination of Cefaclor from the Cerebrospinal Fluid Is Mediated by a Benzylpenicillin-Sensitive Mechanism Distinct from Organic Anion Transporter 3 (2005) (20)
Clinical Relevance of Liquid Chromatography Tandem Mass Spectrometry as an Analytical Method in Microdose Clinical Studies (2011) (20)
Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity (2014) (20)
Analysis of Pharmaceutical Safety-Related Regulatory Actions in Japan: Do Tradeoffs Exist Between Safer Drugs and Launch Delay? (2010) (20)
Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. (2012) (20)
SLCO1A2-MDCKII: a Promising in vitro System to Understand the Role of OATP1A2 in Blood Brain Barrier Drug Penetration (2015) (20)
Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects (2017) (20)
Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. (1997) (19)
Effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding: Use of fluorescent probes (1984) (19)
In vivo and in vitro evidence for nonrestricted transport of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. (1997) (19)
Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure—Pharmacokinetic relationships (1988) (19)
Carrier-mediated active transport of the glucuronide and sulfate of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) into rat liver: quantitative comparison of permeability in isolated hepatocytes, perfused liver and liver in vivo. (1997) (19)
Kinetic Analysis of the Disposition of Insulin-Like Growth Factor 1 in Healthy Volunteers (2001) (19)
Physicochemical Parameters Responsible for the Affinity of Methotrexate Analogs for Rat Canalicular Multispecific Organic Anion Transporter (cMOAT/MRP2) (2001) (19)
Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. (2010) (19)
Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. (2002) (19)
Galactosyldiacylglycerol, a mammalian DNA polymerase alpha-specific inhibitor from a sea alga, Petalonia bingbamiae. (2001) (19)
Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. (2002) (19)
Clinical Development and Review Times for New Drugs in Japan: Associated Factors (2010) (19)
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2. (2012) (18)
Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921 (2008) (18)
Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. (2017) (18)
Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model. (2015) (18)
Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine (2019) (18)
Involvement of rat organic anion transporter 3 in the uptake of an organic herbicide, 2,4-dichlorophenoxyacetate, by the isolated rat choroid plexus. (2004) (18)
Cytosolic bile acid binding protein in rat liver: Radioimmunoassay, molecular forms, developmental characteristics and organ distribution (1986) (17)
Bile salt export pump (BSEP/ABCB11): trafficking and sorting disturbances. (2013) (17)
Transfected Rat cMOAT Is Functionally Expressed on the Apical Membrane in Madin-Darby Canine Kidney (MDCK) Cells (1998) (17)
Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. (2017) (17)
Efflux mechanism of taurocholate across the rat intestinal basolateral membrane. (2006) (17)
Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment (2014) (17)
Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells. (1987) (17)
Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals (2012) (17)
Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat (1999) (17)
Organ Impairment—Drug–Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs (2015) (17)
Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. (1998) (17)
Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. (2015) (17)
Cost-effectiveness analysis of microdose clinical trials in drug development. (2013) (17)
Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine. (2000) (17)
Receptor-mediated disposition of polypeptides: Kinetic analysis of the transport of epidermal growth factor as a model peptide using in vitro isolated perfused organs and in vivo system☆ (1990) (17)
Chromatographic zinc isotope separation by phenol formaldehyde benzo crown resin. (2006) (17)
Differential Roles of Ubiquitination in the Degradation Mechanism of Cell Surface–Resident Bile Salt Export Pump and Multidrug Resistance–Associated Protein 2 (2014) (17)
Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. (2013) (17)
Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction (2019) (17)
Inter-individual variability of in vivo CYP2D6 activity in different genotypes. (2012) (17)
Involvement of Organic Cation Transporters in the Clearance and Milk Secretion of Thiamine in Mice (2015) (17)
The synthesis of [18F]pitavastatin as a tracer for hOATP using the Suzuki coupling. (2015) (16)
Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. (1998) (16)
Effect of aminoguanidine on lipopolysaccharide-induced changes in rat liver transporters and transcription factors. (2008) (16)
Calpain-mediated cleavage negatively regulates the expression level of ABCG1. (2011) (16)
Quantitative Investigation of the Brain-to-Cerebrospinal Fluid Unbound Drug Concentration Ratio under Steady-State Conditions in Rats Using a Pharmacokinetic Model and Scaling Factors for Active Efflux Transporters (2014) (16)
Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide. (1996) (16)
Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. (1998) (16)
Pharmacokinetics of CPT-11 in rhesus monkeys (1997) (16)
Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics (2018) (16)
Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling (2018) (16)
Acid-catalyzed reaction of ethyl cyanoformate with aromatic amines in acetic acid: facile synthesis of N-substituted amidinoformic acids and ethyl 4-quinazolone-2-carboxylate (1978) (15)
Changes in Pharmacokinetics of Valproic Acid in Guinea Pigs from Birth to Maturity (1985) (15)
A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics. (2014) (15)
Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203. (2013) (15)
Triple hydrogen bond directed crystal engineering of metal assembled complexes: the effect of a bifunctional ligand on supramolecular structure (2000) (15)
Organic anion-binding by human hepatic GSH S-transferases. (1986) (15)
Renal handling of biphosphonate alendronate in rats (1999) (15)
Catalytic cooperativity and subunit interactions in Escherichia coli glutamine synthetase: binding and kinetics with methionine sulfoximine and related inhibitors. (1982) (15)
Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion–transporting polypeptides (2020) (15)
Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. (1998) (15)
Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. (1999) (15)
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers (2020) (14)
Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development (2018) (14)
Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. (1999) (14)
Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up (2004) (14)
Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin (2018) (14)
In Vitro–In Vivo Scale‐up of Drug Transport Activities (2006) (14)
A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. (1993) (14)
Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study. (2013) (14)
Solubility of Uranyl Nitrate Precipitates with N-Alkyl-2-pyrrolidone Derivatives (Alkyl = n-Propyl, n-Butyl, iso-Butyl, and Cyclohexyl) (2009) (14)
Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate. (2013) (14)
Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. (1995) (14)
Dynamic Analysis of GI Absorption and Hepatic Distribution Processes of Telmisartan in Rats Using Positron Emission Tomography (2012) (13)
On the binding of L-S- and L-R-diastereoisomers of the substrate analog L-methionine sulfoximine to glutamine synthetase from Escherichia coli. (1982) (13)
Crystal structures and magnetic properties of novel coordination polymers with rectangular lattice constructed from pyrazine derivative (2001) (13)
Renal Clearance of a Recombinant Granulocyte Colony-Stimulating Factor, Nartograstim, in Rats (1995) (13)
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer (2015) (13)
Synthesis and Substitution of 1,3,4,6-Tetra-substituted-3,6-dihalogeno-2,5-piperazinediones (1973) (13)
Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: comparison between in vitro and in vivo disposition. (1997) (12)
Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. (1996) (12)
MULTIPLICITY OF SULFOBROMOPHTHALEIN-BINDING PROTEINS IN Y-FRACTION FROM RAT LIVER (1979) (12)
Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. (1999) (12)
Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models. (2017) (12)
Identification and partial purification of a unique phenolic steroid sulphotransferase in rat liver cytosol. (1984) (12)
Organic Anion Transporting Polypeptide 1a4 is Responsible for the Hepatic Uptake of Cardiac Glycosides in Mice (2018) (12)
Evidence that interference with binding to hepatic cytosol binders can inhibit bile acid excretion in rats (1996) (12)
Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion. (1993) (12)
Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. (1998) (12)
Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B‐mediated hepatic uptake (2018) (12)
Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay. (2016) (12)
Asian Journal of Pharmacodynamics and Pharmacokinetics (2009) (12)
Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats. (1995) (11)
Nonlinear pharmacokinetics of hepatobiliary transport of rose bengal in rats after iv bolus administration with varying doses (1992) (11)
Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. (1999) (11)
First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use (2011) (11)
In vivo Cisplatin Resistance Depending upon Canalicular Multispecific Organic Anion Transporter (cMOAT) (1999) (11)
Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism. (2013) (11)
Adsorptivity of silica-supported adsorbents impregnated with polyphosphine polyoxides to U(VI) and some other metal ions in nitric acid media (2010) (11)
Binding of lithocholate and its glucuronide and sulfate by human serum albumin. (1995) (11)
Interindividual pharmacokinetics variability of the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), in beagles is associated with albumin genetic polymorphisms. (2009) (11)
Characterization of the Transport Properties of a Quinolone Antibiotic, Fleroxacin, in Rat Choroid Plexus (1996) (11)
Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer (2005) (11)
Identification of hepatic Z-protein in a marine elasmobranch, Platyrhinoides triseriata. (1982) (11)
Bafilomycin A1-sensitive pathway is required for the maturation of cystic fibrosis transmembrane conductance regulator. (2006) (11)
Importance of pharmacokinetic considerations in the development of drug delivery systems (1996) (11)
Expression and Functional Characterization of Rat Organic Anion Transporter 3 ( rOat 3 ) in the Choroid Plexus (2002) (11)
Brain Efflux Index Method (2003) (10)
Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. (2018) (10)
An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development. (2015) (10)
Characterization of the Enhancing Effect of Protamine on the Proliferative Activity of Hepatocyte Growth Factor in Rat Hepatocytes (2009) (10)
A Novel Hepatic-Targeting System for Therapeutic Cytokines That Delivers to the Hepatic Asialoglycoprotein Receptor, but Avoids Receptor-Mediated Endocytosis (2002) (10)
Bile acid profiles in analbuminemia rats. (1985) (10)
Reversed-phase high-performance thin-layer chromatography of hematoporphyrin and its nickel, copper and zinc complexes (1986) (10)
Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen (2018) (10)
Prediction of Human Bioavailability from Human Oral Administration Data and Animal Pharmacokinetic Data Without Data from Intravenous Administration of Drugs in Humans (2009) (10)
Syntheses of N-Substituted Carbamimidoylformic Acids (1971) (10)
Pharmacokinetic Aspects of Peptide Delivery and Targeting: Importance of Receptor-Mediated Endocytosis (1994) (9)
Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations. (1996) (9)
Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging. (2019) (9)
Factors associated with spontaneous reporting of adverse drug reactions in Japan (2013) (9)
The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. (1996) (9)
Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. (2016) (9)
Analysis of citrulline in rat brain tissue after perfusion with haloperidol by liquid chromatography-mass spectrometry. (2000) (9)
Transport properties of 3′‐azido‐3′‐deoxythymidine and 2′,3′‐dideoxyinosine in the rat choroid plexus (1997) (9)
Up-Regulation of Carnitine Transporters Helps Maintain Tissue Carnitine Levels in Carnitine Deficiency Induced by Pivalic Acid (2001) (9)
Active efflux across the blood-brain barrier: Role of the solute carrier family (2005) (9)
Determination of the Rate-Limiting Step in the Hepatic Elimination of YM796 by Isolated Rat Hepatocytes (2004) (9)
Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. (1999) (9)
Phosphorylated PKR contributes the induction of GRP94 under ER stress. (2007) (9)
Primary active transport of organic anions on bile canalicular membrane in humans. (1999) (9)
Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes. (1997) (9)
Effect of phenobarbitone on the distribution and elimination of imipramine in rats (1985) (9)
Proton-transfer-mediated crystal engineering using 1,4,5,6-tetrahydro-5,6-dioxo-2,3-pyrazinedicarbonitrile with 4,4′-bipyridine (2002) (8)
Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method (2010) (8)
Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance (2022) (8)
Brain efflux index method. Characterization of efflux transport across the blood-brain barrier. (2003) (8)
Effect of quinidine on the tissue binding of digoxin in guinea‐pigs (1986) (8)
High-performance liquid chromatographic separation of hematoporphyrin and its nickel, copper and zinc complexes on octadecyl-bonded stationary phase (1986) (8)
Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered? (2017) (8)
Adsorptivity of silica-supported monoamide resins to U(IV) in nitric acid media (2010) (8)
Kinetic Analysis of Transcytosis of Epidermal Growth Factor in Madin-Darby Canine Kidney Epithelial Cells (1997) (8)
Treatment of Hyperbilirubinemia in Eisai Hyperbilirubinemic Rat by Transfecting Human MRP2/ABCC2 Gene (2005) (8)
Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. (1999) (8)
Addition of Methanesulfenyl Chloride and Sulfur Chloride to 1,4-Dimethyl-3,6-dimethylene-2,5-piperazinedione and Substitution of the Adducts (1974) (8)
Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. (2016) (8)
Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies (2012) (8)
Structural Requirements for Alkylglycoside-Type Renal Targeting Vector (1999) (8)
The role of breast cancer resistance protein (Bcrp/Abcg2) in triptolide-induced testis toxicity (2015) (8)
Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes (1993) (7)
Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships (2019) (7)
Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. (2008) (7)
Analysis of Nonlinear Hepatic Clearance of a Cyclopentapeptide, BQ-123, with the Multiple Indicator Dilution Method Using the Dispersion Model (2004) (7)
Short- and medium-chain fatty acids enhance the cell surface expression and transport capacity of the bile salt export pump (BSEP/ABCB11). (2010) (7)
Assessment of the contribution of α1‐acid glycoprotein to the serum binding of basic drugs using serum treated with sulphosalicylic acid and DEAE‐cellulose (1985) (7)
Kinetics of Quinolone Antibiotics in Rats: Efflux from Cerebrospinal Fluid to the Circulation (1996) (7)
Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects. (2017) (7)
Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure (2012) (7)
[Reconstruction of drug dispositions in vivo from in vitro studies based on physiological pharmacokinetic modeling: from low-molecular weight drugs to polypeptide compounds]. (1989) (7)
Radiosynthesis of novel pitavastatin derivative ([18 F]PTV-F1) as a tracer for hepatic OATP using a one-pot synthetic procedure. (2016) (7)
In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines (2018) (7)
Binding of glutathione by rat liver cytosol. (1984) (7)
Purification of haematoporphyrin IX by extraction and reversed-phase chromatography. (1986) (7)
Contribution of Parenchymal and Non-Parenchymal Liver Cells to the Clearance of Hepatocyte Growth Factor From the Circulation in Rats (1995) (7)
Drug transfer in the choroid plexus. Multiplicity and substrate specificities of transporters (2004) (6)
Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802 (2016) (6)
Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. (2019) (6)
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARα-mediated redistribution of ABCB4 Published, JLR Papers in Press, July 16, 2004. DOI 10.1194/jlr.M400132-JLR200 (2004) (6)
Relationship between content of hepatic glutathione S‐transferases and the kinetics of indocyanine green elimination in various liver diseases (1993) (6)
[Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport]. (1995) (6)
In Vivo Characterization of Interactions on Transporters (2013) (6)
Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective (2022) (6)
Efflux transport systems at the blood–brain barrier and blood CSF barrier (2005) (6)
Expanded PBPK Model of Rifampicin for Predicting Interactions with Drugs and an Endogenous Biomarker via Complex Mechanisms including OATP1B Induction. (2019) (6)
Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. (2001) (6)
Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics (2019) (6)
Kinetic and Mechanistic Studies on Reactions of Pyrrolidone Derivatives with Ozone (2011) (6)
A Study on Zinc Isotope Fractionation in a Benzo Crown Resin/Acetone System (2006) (6)
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity. (2012) (6)
Theoretical consideration of drug distribution kinetics in a noneliminating organ: Comparison between a “homogeneous (well-stirred)” model and “nonhomogeneous (tube)” model (1985) (6)
High-Speed Data Position Detection Method Using Template Matching for Hologram Memory (2004) (6)
Comparison of the effects of bile acids and GSH on the fluorescence of bound 1-anilino-8-naphthalene sulfonate and the enzymatic activity of cationic and neutral human hepatic GSH S-transferases. (1988) (6)
Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions. (2010) (5)
Use of an isolated perfused kidney to assess renal clearance of drugs: information obtained in steady-state and non-steady-state experimental systems. (1996) (5)
Significance of Binding to Na,K-ATPase in the Tissue Distribution of Ouabain in Guinea Pigs (1992) (5)
Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans. (2017) (5)
Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. (2017) (5)
[Kinetic analysis of the disposition of hydrophilic drugs in the central nervous system (CNS): prediction of the CNS disposition from the transport properties in the blood-brain and blood-cerebrospinal fluid barriers]. (1994) (5)
Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells. (2005) (5)
Transient, tunable expression of NTCP and BSEP in MDCKII cells for kinetic delineation of the rate-determining process and inhibitory effects of rifampicin in hepatobiliary transport of taurocholate. (2020) (5)
THE CORRELATION BETWEEN DRUG BINDING TO THE HUMAN ERYTHROCYTE MEMBRANE AND ITS HEMOLYTIC ACTIVITY, DETERMINED BY FLUORESCENT PROBE TECHNIQUES (1978) (5)
Kinetic Modeling of Ouabain Tissue Distribution Based on Slow and Saturable Binding to Na,K-ATPase (1992) (5)
Effect of a diffusional barrier to a metabolite across hepatocytes on its kinetics in “enzyme-distributed” models: A computer-aided simulation study (1987) (5)
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo. (2021) (5)
Human Plasma Concentrations of Tolbutamide and Acetaminophen Extrapolated from in vivo Animal Pharmacokinetics Using in vitro Human Hepatic Clearances and Simple Physiologically Based Pharmacokinetic Modeling for Radio-labeled Microdose Clinical Studies (2015) (5)
Medication Episode Construction Framework for Retrospective Database Analyses of Patients With Chronic Diseases (2018) (5)
Alteration of Pharmacokinetic Features Caused by Drug Interactions (1995) (5)
Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data. (2017) (5)
Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes. (2002) (5)
Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologica (2017) (4)
GLYCOPROTEIN BY VALSPODAR IN GENE TRANSFECTANT SYSTEMS (2000) (4)
Kinetic analysis of the dose-dependent hepatic handling of 1-anilino-8-naphthalene sulfonate in rats (1990) (4)
Quantitative Prediction of In Vivo Drug-drug Interactions from In Vitro Data : Effects of Active Transport of Inhibitors into the Liver (2000) (4)
INTERINDIVIDUAL DIFFERENCES IN THE PLASMA PROTEIN BINDING OF 1-ANILINO-8-NAPHTHALENESULFONATE AND PHENYLBUTAZONE IN RATS (1979) (4)
Future prospects for toxicokinetics: its ability to predict drug adverse events in humans. (1996) (4)
Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs (2016) (4)
Prediction of Hepatic Clearance in Humans from Experimental Animals and In Vitro Data (2003) (4)
Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments. (2016) (4)
Extrapolation of In Vitro Metabolic and P-Glycoprotein-Mediated Transport Data to In Vivo by Modeling and Simulations (2010) (4)
Delivery of Drugs and Antisense Oligonucleotides to the Proximal Tubular Cell of the Kidney Using Macromolecular and Pro‐drug Approaches (2001) (4)
Renal Tubular Handling of p-Aminohippurate and Epidermal Growth Factor (EGF) in Filtering and Nonfiltering Perfused Rat Kidneys (1992) (4)
Improved prediction of the drug-drug interactions of pemafibrate caused by cyclosporine A and rifampicin via PBPK modeling: Consideration of the albumin-mediated hepatic uptake of pemafibrate and inhibition constants with preincubation against OATP1B. (2020) (4)
Differences in Substrate Specificity among Glutathione Conjugates (GS‐X) Pump Family Members: Comparison between Multidrug Resistance‐associated Protein and a Novel Transporter Expressed on a Cisplatin‐resistant Cell Line (KCP‐4) (1999) (4)
Future prospects for toxicokinetics: prediction of drug disposition and adverse effects in humans from in vitro measurements of drug metabolism, transport and binding. (1998) (4)
Comparison of binding of thyroid hormone analogues to hepatic organic anion binding proteins. (1984) (4)
[Kinetics of receptor-mediated endocytosis of polypeptide hormones that governs the overall hormone disposition in the body: analysis of the uptake process of epidermal growth factor by the liver and kidney]. (1991) (4)
Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs (2020) (4)
Stability of pyrrolidone derivatives against γ-ray irradiation (2012) (4)
Hydroxyprolylserine Derivatives JBP 923 and JBP 485 Exhibit the Antihepatitis Activities after Gastrointestinal Absorption in Rats 1 (2000) (4)
[Role of transporters in the detoxification of xenobiotics: recent advances in the study of cMOAT/MRP]. (1997) (4)
Protamine enhances the proliferative activity of hepatocyte growth factor in rats. (1998) (4)
Quantitation and characterization of a newly described organic anion binder by radioimmunoassay. (1984) (4)
Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes. (2020) (4)
An Attempted Synthesis of 3,6-Epidithio-2,5-piperazinedione by Cyclization of N,N′-dialkyl-2,2′-dithiodicinnamamide (1972) (4)
Revealing oral medication patterns from reconstructed long-term medication history of type 2 diabetes (2016) (4)
Transport of sulfated conjugates by human breast cancer resistance protein (BCRP/ABCG2) (2002) (3)
Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters. (2017) (3)
Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers. (2016) (3)
Synthesis and Crystal Structure of One-Dimensional Copper(II) Coordination Polymer Bridged by Pyrazine Derivative (2002) (3)
New strategy for drug development with exploratory IND studies: scientific basis and future directions. (2011) (3)
Experimental and Modeling Evidence Supporting the Trans-Inhibition Mechanism for Preincubation Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting Polypeptide 1B1 by Cyclosporine A (2022) (3)
Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method (2013) (3)
Triple Hydrogen Bond Directed Crystal Engineering of Metal Assembled Complexes: The Effect of a Novel Organic-Inorganic Module on Supramolecular Structure (2002) (3)
Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A. (2021) (3)
Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. (1999) (3)
Effect of basic drugs on the hepatic uptake of ouabain by sinusoidal plasma membrane vesicles isolated from rat liver (1992) (3)
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney (2022) (3)
Prediction of Hepatic Transporter-Mediated Drug–Drug Interaction from In Vitro Data (2013) (3)
Comparative hepatic transport of desglycylated and cyclic metabolites of rilmazafone in rats: Analysis by multiple indicator dilution method (1993) (3)
QUANTITATIVE PREDICTION: METABOLISM, TRANSPORT IN THE LIVER (1999) (3)
Zinc Isotope Separation by Phenol Formaldehyde Type 15-Crown-5 Resin in Organic Solvents (2006) (3)
[Quantitative analysis of cell-kill effects of anticancer drugs: consideration of both in vitro and in vivo experimental systems]. (1987) (3)
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions (2022) (3)
Evaluation of [11C]oseltamivir uptake into the brain during immune activation by systemic polyinosine-polycytidylic acid injection: a quantitative PET study using juvenile monkey models of viral infection (2014) (3)
Correlation Between the Inhibitory Effects of Basic Drugs on the Uptake of Cardiac Glycosides and Taurocholate by Isolated Rat Hepatocytes (1992) (3)
Saturable Process Involved in Active Efflux of Vincristine as a Mechanism of Multidrug Resistance in P388 Leukemia Cells (1989) (3)
Plasma Calcium Level‐responsive Oestradiol Release From Self‐setting Apatitic Bone Cement in Ovariectomized Rats (1996) (3)
One-dimensional helical chain in the co-crystal of CHCl3 and trans-2,3,5,6,11,11b-hexahydro-3-oxo-1H-indolizino[8,7-b]indole-5-carboxylic acid methyl ester: a channel-type inclusion complex (2001) (3)
A NEW ROUTE FOR SYNTHESIS OF 3,6-DIALKYL-1,4-DIMETHYL-3,6-EPITHIO-AND -3,6-EPIDITHIO-2,5-PIPERAZINEDIONES (1974) (3)
Uptake of Colchicine, a Microtubular System Disrupting Agent, by Isolated Rat Hepatocytes (1989) (3)
Modulation of the tumor disposition of vinca alkaloids by PSC 833 in vitro and in vivo. (1998) (3)
Bio-sorption of acidic gelatine hydro-gels implanted in the back tissues of Fisher's rats. (2005) (3)
Precipitation ability to U(IV) and stability of 1,3-dimethyl-2-imidazolidone for selective precipitation of U(VI) in nitric acid media (2011) (3)
Report 3 : FUTURE PROSPECTS FOR TOXICOKINETICS : ITS ABILITY TO PREDICT DRUG ADVERSE EVENTS IN HUMANS ( TOXICOKINETICS) (1996) (3)
Web-Based Database as a Tool to Examine Drug–Drug Interactions Involving Transporters (2010) (3)
Localization of Epidermal Growth Factor (EGF) Binding Sites on Antiluminal Plasma Membrane of Rat Kidney: Autoradiographic Study Using Nonfiltering Perfused Rat Kidney (2004) (3)
Coordination of Uptake and Efflux Transporters in Drug Disposition (2007) (2)
Relative activity factor (RAF)-based scaling of uptake clearance of OATP1B substrates from transfected cell systems to human hepatocytes and to in vivo (2019) (2)
Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents (2007) (2)
Effect of Pd(II) Species on Decomposition Reactions of Pyrrolidone Derivatives by Ozone (2012) (2)
Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. (1999) (2)
[The role of P-glycoprotein in the liver]. (1997) (2)
Lack of Contribution of P-Glycoprotein (P-gp) to Transport via the Mouse Blood-Cerebrospinal Fluid Barrier (2005) (2)
ACTIVE EFFLUX OF RO 64-0802, THE ACTIVE FORM OF OSELTAMIVIR, ACROSS THE BLOOD-BRAIN BARRIER (2008) (2)
Detection of the Membrane Protein Recognized by the Kidney-Specific Alkylglucoside Vector (2004) (2)
The Concept of "Conformation" and the "Combinatorial Approach" for Parameter Estimation in a Multi-compartment Model System (1988) (2)
Localization of Binding Sites for Epidermal Growth Factor (EGF) in Rat Kidney: Evidence for the Existence of Low Affinity EGF Binding Sites on the Brush Border Membrane (1992) (2)
The molecular and immunohistochemical expression of multidrug resistance-associated protein (MRP) 3 in the liver and intestine of patients with cholestasis and its biological significance (2000) (2)
Chapter 11. Hepatic Transport (2009) (2)
Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. (1998) (2)
MECHANISM OF CELLULAR UPTAKE OF ANTISENSE DNA (1994) (2)
Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. (1999) (2)
Breast Cancer Resistance Protein Substrate and Inhibition Evaluation: Why, When, and How? (2014) (2)
HEPATIC TRANSPORT OF PKI 166 , AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS , AND ITS MAIN METABOLITE , ACU 154 (2004) (2)
THE BINDING AND CONJUGATING ABILITIES OF THE Y-FRACTION FOR SULFOBROMOPHTHALEIN (BSP) IN CHRONIC CARBON TETRACHLORIDE-INTOXICATED RATS (1979) (2)
Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of S-8921 glucuronide , a pharmacologically active metabolite of S-8921 (2008) (2)
Vectorial Transport of Enalapril by Oatp 1 a 1 / Mrp 2 and OATP 1 B 1 and OATP 1 B 3 / MRP 2 in Rat and Human Livers (2006) (2)
Effects of calmodulin antagonists on secretion of bile and bile acid (1987) (1)
323 A clinical pharmacokinetic microdosing study of docetaxel with Japanese cancer patients (2015) (1)
Practical synthesis of [18F]pitavastatin and evaluation of hepatobiliary transport activity in rats by positron emission tomography. (2020) (1)
Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy (2021) (1)
Frequency of null genotypes of glutathione S‐transferase M1 and T1 in Japanese patients with drug‐induced liver injury (2022) (1)
Corrigendum to "Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data" [Drug Metab Pharmacokinet 32 (2017) 135-144]. (2017) (1)
QUANTITATIVE EVIDENCE FOR INTERSPECIES DIFFERENCE IN TISSUE DISTRIBUTION MECHANISM OF ADRIAMYCIN (1982) (1)
Importance of Reverse Translational Research (rTR). (2017) (1)
Development of unmanned caisson type pile installing system (2017) (1)
Investigation of the effect of mutations of rat albumin on the binding affinity to the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), using recombinant rat albumins. (2010) (1)
Role of Pharmacokinetic and Transporter Studies in Drug Design. (1999) (1)
Protamine enhances the proliferative activity of hepatocyte growth factor in rats. (1998) (1)
Analysis of Labeling Decisions Regarding Therapeutic Indications During New Drug Application Reviews in Japan (2011) (1)
UPTAKE TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS. (2005) (1)
EFFECT OF PREGNANCY ON TISSUE DISTRIBUTION OF SALICYLATE IN THE RAT (1984) (1)
Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers (2018) (1)
Automated Extraction of Information on Chemical-P-glycoprotein Interactions from the Literature (2013) (1)
Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers (2019) (1)
SLCO1B1 polymorphisms affect atorvastatin pharmacokinetics and cholesterol-lowering effects in patients with hypercholesterolemia in a microdosing approach (2013) (1)
[Polarized expression of drug transporters and its physiological significance]. (2003) (1)
QUANTITATIVE SEPARATION AND ANALYSIS OF DIASTEREOISOMERS OF L-METHIONINE S,R-SULFOXIMINE VIA CYCLIC N-BLOCKED DERIVATIVES (1983) (1)
Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides. (2020) (1)
Quantitative separation and analysis of diastereomers of L-methionine-S,R-sulfoximine via cyclic N-blocked derivatives (1983) (1)
Evaluation of hepatic transport function by hepatobiliary scintigraphy (1992) (1)
Functional characterization of mouse Oatp 1 a 4 in the uptake and efflux of drugs across the blood – brain barrier (2009) (1)
QUANTITATIVE PREDICTION OF IN VIVO METABOLIC CLEARANCE AND DRUG-DRUG INTERACTIONS IN HUMANS BASED ON IN VTIRO STUDIES (1997) (1)
[Transport proteins for drugs and bile acids in the liver cytosol and plasma membrane--its multiplicity and functions]. (1990) (1)
Comparison of the Methods for Determining Cell-Surface and Intracellular Receptors for Epidermal Growth Factor in the Rat Liver (1991) (1)
Renal handling of epidermal growth factor in isolated perfused rat kidney (1990) (1)
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity. (2022) (1)
INVOLVEMENT OF MOUSE OATP1A4 IN THE UPTAKE OF ORGANIC ANIONS ACROSS THE BLOOD-BRAIN BARRIER (2006) (0)
BILIARY EXCRETION MECHANISM OF IRINOTECAN CPT-1 1 AND ITS METABOLITES IN HUMANS AND RATS: INVOLVEMENT OF cMOAT and P-gp (1998) (0)
EFFECT OF P-GLYCOPROTEIN ON ORAL DRUG ABSORPTION -QUANTITATIVE EVALUATION OF IN VIVO INTESTINAL PERMEABILITY OF P-GLYCOPROTEIN SUBSTRATE DRUGS- (2006) (0)
Feature and evaluation of drug delivery system targeted to receptor-mediated endocytosis. (1994) (0)
SUBSTRATE RECOGNITION/TRANSPORT MECHANISM OF RAT MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (2000) (0)
EFFECT OF 17 (cid:1) -ESTRADIOL- D -17 (cid:1) -GLUCURONIDE ON THE RAT ORGANIC ANION TRANSPORTING POLYPEPTIDE 2-MEDIATED TRANSPORT DIFFERS DEPENDING ON SUBSTRATES (2002) (0)
Comparative analysis of hepatic uptake and biliary excretion of vincristine and vinblastine in perfused rat liver (1990) (0)
What determines exercise performance in congenital heart disease / New frontiers in lipid lowering 17 (2015) (0)
Radiosynthesis of [18F]PTV-F1, pitavastatin (HMG-CoA reductase inhibitor) derivative for Organic Anion Transporter Imaging of Liver (2015) (0)
DMD049460 362..371 (2013) (0)
Development of Tricalcium Phosphate-Collagen Immobilized Tetracycline Complex Implant. (1991) (0)
REVIEW ARTICLE PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKTNETICS (1996) (0)
S9.1 - Albumin-mediated hepatic uptake of organic anion transport polypeptide substrates (2020) (0)
Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values (2011) (0)
薬物に関する生理学基礎薬物動態(PB‐PK)モデルに関する適用と展望 (1995) (0)
QUANTITATIVE INVESTIGATION OF THE SYNERGISTIC ROLE OF P-GLYCOPROTEIN (P-GP/ABCB1) AND BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) IN LIMITING THE BRAIN AND TESTIS PENETRATION OF ERLOTINIB AND MITOXANTRONE (2009) (0)
Hepatobiliary Transport of folates and Antifolates (1999) (0)
Drug-drug interaction based on the inhibition on the transporter-mediated hepatic uptake (DRUG METABOLISM) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting) (2003) (0)
29 S 5 B-3 HYPOCHOLESTEROLEMIC ACTION AND HEPATOBILIARY TRANSPORT OF METHYL-1-( 3 , 4-DIMETHOXYPHENYL )-3-( 3-ETHYLVALERYL )-4-HYDROXY-6 , 7 , 8-TRIMETHOXY-2-NAPHTHOATE ( S-8921 ) GLUCURONIDE (2006) (0)
restricts the of across the (2007) (0)
SCIENCE FOR THE EXTRAPOLATION OF PHARMACOKINETIC PROPERTIES TO HUMAN IN THE NEW MILLENNIUM ENTERING THE PARADIGM SHIFT OF DRUG DISCOVERY AND DEVELOPMENT (2000) (0)
INVESTIGATION OF THE INHIBITORY EFFECTS OF VARIOUS THERAPEUTIC DRUGS ON OATP1B3-MEDIATED UPTAKE OF FEXOFENADINE (2006) (0)
Functional Analysis of SNPs in Human OATP2 (OATP-C/SLC21A6) (2003) (0)
Receptor-Mediated Targeting of Peptides and Proteins (1996) (0)
Inhibitory effect of a sialyl Lewis X analog on human colon carcinoma metastasis (1998) (0)
Analysis of the Human Hepatic Uptake Mechanism of Ursodeoxycholic Acid and its Conjugates (2003) (0)
Analysis of drug‐drug interactions caused by the inhibition of hepatic organic anion transporting polypeptides using a rational physiologically based pharmacokinetic model and parameters obtained from human hepatocytes (2016) (0)
KINETIC STUDIES ON FORMATION AND BILIARY EXCRETION OF LIQUIRITIGENIN CONJUGATES IN RATS (1992) (0)
MULTIPLE ORGANIC ANION TRANSPORTERS INVOLVED IN BLOOD-BRAIN BARRIER TRANSPORT (2009) (0)
459 Changes of mRNA levels for prolactin receptor in the brain, liver, and, kidney of virgin, pregnant and lactating rats. (1991) (0)
22D-11-2 Modifying the pharmacokinetics of the anticancer drug CPT-11, and its active metabolite SN-38, aimed at reducing the biliary excretion of SN-38 and its gastrointestinal toxicity. (1999) (0)
Internalization of epidermal growth factor by the hepatocytes is a receptor occupancy-independent event (1990) (0)
Evaluation of the involvement of multiple transporters and their contribution to the hepatic uptake and efflux of drugs in humans (2005) (0)
QUANTITATIVE PREDICTION OF DRUG-DRUG INTERACTIONS: MECHANISM-BASED INHIBITION OF DRUG METABOLISM (1998) (0)
Hepatic Drug Metabolism (2004) (0)
Kinetic analysis of hepatic transport of drugs. (1986) (0)
CONSTRUCTION OF A WEB-BASED SYSTEM FOR THE PREDICTION OF MAJOR CLEARANCE PATHWAY OF DRUGS FROM THEIR PHYSICOCHEMICAL PROPERTIES (2010) (0)
KINETICAL ANALYSIS OF HEPATIC TRANSPORT OF EPIDERMAL GROWTH FACTOR (EGF) IN THE PERFUSED RAT LIVER (1987) (0)
Abstracts (2009) (0)
For peer review only Assessment of statin -associated severe muscle toxicity in Japan: A cohort study by using a claims database and laboratory information (2012) (0)
The role of MRP family proteins in detoxification of xenobiotics in liver and intestine. (1999) (0)
Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs (2019) (0)
Kinetic analysis of various factors (activities for conjugation, deconjugation and membrane transport) governing the pharmacokinetics of conjugative metabolites (1993) (0)
Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse (2015) (0)
JPET #206425 1 Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion using Newly Developed Positron Emission Tomography (PET) Tracer, [C]Dehydropravastatin, in Rats (2013) (0)
Down regulation of epidermal growth factor (EGF) receptor in the perfused rat liver : recovery of the cell surface free receptor (1990) (0)
[Transporters and molecular-targeted drugs]. (2012) (0)
Title Regulation of Tissue-specific Expression of Renal Organic Anion Transporters by Hepatocyte Nuclear Factor 1 α / β and DNA Methylation (2011) (0)
Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins (2013) (0)
Faculty Opinions recommendation of Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. (2006) (0)
Effect of the Fluoroquinolone Antibacterial Agent DX-619 on the Apparent Formation and Renal Clearances of 6β-Hydroxycortisol, an Endogenous Probe for CYP3A4 Inhibition, in Healthy Subjects (2012) (0)
Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines (2013) (0)
Drug transporters: Starring roles in new drug discovery and development (2017) (0)
P-227 Increased sinusoidal efflux and decreased excretion of bile acids by the inhibition of binding to the cytosol Y' bile acid binders (BAB) (1995) (0)
VIRTUAL CLINICAL TRIAL (I):ASSOCIATION OF INTERINDIVIDUAL VARIABILITY IN PHARMACOKINETICS WITH CYP2D6 GENOTYPES (2009) (0)
Polymorphisms of Two Anion Transporters (OATP-C and MRP2) Genes - Consequences for Pravastatin Pharmacokinetics (2003) (0)
PHARMACOKINETICS OF CAPECITABINE, OF TRIPLE-PRODRUG OF 5-FU: USEFULNESS OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR QUANTITATIVE UNDERSTANDING OF TUMOR-SELECTIVE DISTRIBUTION OF 5-FU AFTER ORAL ADMINISTRATION OF THE TRIPLE-PRODRUG (2001) (0)
SPECIES DIFFERENCE IN DRUG METABOLIZING ACTIVITY IN SMALL INTESTINE (1999) (0)
Genipin, an active metabolite of a herbal medicine, inchinko-to, enhances multidrug resistance-associated protein 2 (Mrp2)-mediated bile formation and organic anion transport in the liver (2003) (0)
Role of ABC transporters for the biliary excretion of organic anions (1996) (0)
INNOVATIVE STRATEDIES FOR DRUG DEVELOPMENT USING MICRODOSING CLINICAL STUDIES (NEDO MICRODOSE-PJ) 2010 (1):INTERNATINAL COMPARISON OF REGULATORY DOCUMENTS CONCERNING MICRODOSE CLINICAL TRIAL (2010) (0)
[Overview: molecular variation, specific tissue localization and genetic polymorphisms of drug transporters]. (2005) (0)
BINDING, INTERNALIZATION AND DEGRADATION OF ATRIAL NATRIURETIC PEPTIDE IN ISOLATED CHOROID PLEXUS (1990) (0)
Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method (2013) (0)
Involvement of Organic Cation Transporters in the Clearance and Milk Secretion of Thiamine in Mice (2015) (0)
TELMISARTAN IN RATS (2009) (0)
21C-04-3 Is It Possible to Quantitatively Predict In Vivo Drug Metabolizing Activity of Cytochrome P450 in Human Liver from In Vitro Metabolic Studies ? (1999) (0)
INVESTIGATION OF FGF23-MEDIATED REGULATION OF RENAL TRANSPORTERS (2009) (0)
CONTRIBUTION OF P-GLYCOPROTEIN, ASSOCIATED WITH MULTIDRUG RESISTANCE, TO BILIARY EXCRETION OF VINCRISTINE : A KINETIC ANALYSIS (1991) (0)
IMPORTANCE OF EVALUATING CONTRIBUTIONS OF TRANSPORTERS IN DRUG DEVELOPMENT: AN APPROACH USING SELECTIVE INHIBITORS (2001) (0)
COMMENTARY Professor Akira Tsuji: Scientist, Educator, and Leader (2011) (0)
Transport systems for organic anions in the blood-brain barrier (2005) (0)
[Pharmacogenomics: the frontiers of genome medicine]. (2002) (0)
[Multiplicity and molecular mechanism of substrate recognition by MRP]. (2001) (0)
Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. (2020) (0)
variant of tissue plasminogen activator, in rodents (2006) (0)
Human organic anion transporters 1 (hOAT1/ ) and 3 (hOAT3/ ) transport edaravone (MCI-186; and its sulfate conjugate. (2007) (0)
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers (2017) (0)
INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT USING MICRODOSING CLINICAL STUDIES (NEDO MICRODOSE-PJ) 2010-(4)-EFFECT OF CURCUMIN ON THE INTESTINAL ABSORPTION OF SULFASALAZINE (2010) (0)
Method for manufacturing ketazines (1979) (0)
Kidney targeting of glycosylated peptides (1997) (0)
THE EFFECT OF BASIC DRUGS ON THE HEPATIC TRANSPORT OF CARDIAC GLYCOSIDES IN RATS (1987) (0)
A process for preparing a forårsulle (1995) (0)
Pet imaging to understand hepatobiliary transporters (2019) (0)
VECTORIAL TRANSPORT OF ORGANIC ANIONS ACROSS LLC-PK1 CELL MONOLAYERS (2004) (0)
A cost model and copyright management for 3D digital contents using multilevel complex objects (2000) (0)
A process for preparing a spring roll (1995) (0)
A traial of image evaluation by quantification theory type III : Examination of words used for evaluation (1997) (0)
Raised Profile Line Marking Detection by MMW Radar System (2017) (0)
Print data transfer process and printer (1999) (0)
Microsoft Word-50328380-file00 (2010) (0)
Revealing oral medication patterns from reconstructed long-term medication history of type 2 diabetes. (2016) (0)
Perspectives of xenobiotics science in Asia Pacific community: Xenobiotic metabolism and transporters – Importance of translational and reverse-translation research (2017) (0)
Glutathione S-transferases inelasmobranch liver Molecular heterogeneity, catalytic andbinding properties, andpurification (1981) (0)
Changes of microvascular patterns and bone regeneration following the hydroxyapatite and tricalcium phosphate implant to periodontal osseous defects in the dog (1992) (0)
Experimental system for imaging in-vivo tissue characteristics (1989) (0)
Importance of Drug Transporter Studies in the New Drug Discovery and Development (2009) (0)
Molecular imaging & DDS (2008) (0)
Role of transporter sciences in new drug discovery and development (2021) (0)
Long-term effectiveness of sulfonylureas in type 2 diabetes (2016) (0)
THE TRANSPORT SYSTEM OF BENZYLPENICILLIN IN THE BLOOD-CEREBROSPINAL FLUID BARRIER (1987) (0)
THE TRANSPORT SYSTEM OF CIMETIDINE FROM THE RAT CEREBROSPINAL FLUID : IN VIVO AND IN VITRO STUDIES (1986) (0)
Inclusion of human intravenous study data in new drug applications-impact of the Japanese guidance. (2012) (0)
Kinetic analysis of the mechanism for disposition of hepatocyte growth factor in rats: Contribution of receptor-mediated endocytosis and non-specific uptake mechanism (1993) (0)
Pharmacophore Estimation and 3D-QSAR of Ligands for Organic Anion Transporting Polypeptide 1B1 (OATP1B1) (2008) (0)
Quantitative Prediction of Drug Interation Involving Metabolism and Transport in the Liver (2000) (0)
Utilization of ATP-depleted cells in t e analysis of tauroc by isolated rat hepatocytes (1992) (0)
Phase-3 Detoxification in the Liver: Biliary Excretion of small molecules and peptides by primary active transport mechanisms (1995) (0)
Role of breast cancer resistance protein in the blood-brain and -testis barriers (2006) (0)
Abstracts of selected papers presented at the 34th annual meeting of the Japanese Society of Gastroenterology October 12–14, 1992, Utsunomiya, Japan (1993) (0)
Kinetic analysis of the distribution of quinolone antibiotics in the central nervous system: Role of active efflux transport from the brain (1996) (0)
Transporters and Drug Interactions (2007) (0)
5. Microdose Clinical Study for Drug Development (2009) (0)
Re: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. (1998) (0)
Preparation et procede permettant d'ameliorer l'absorption gastro-intestinale d'agents pharmaceutiques (2006) (0)
PREDICTION OF IN VIVO HUMAN HEPATIC CLEARANCE IN DRUG DISCOVERY (2000) (0)
Dynamic Analysis of GI Absorption and Hepatic Distribution Processes of Telmisartan in Rats Using Positron Emission Tomography (2012) (0)
INVESTIGATION OF THE IMPORTANCE OF OATP 1 B 3 AND MRP 2 IN DOCETAXEL-INDUCED HEMATOPOIETIC TOXICITY (2009) (0)
ROLE OF MRP FAMILY IN THE DISPOSITION OF XENOBIOTICS (2000) (0)
Sufficient pharmacokinetic and disposition studies using experimental animals are by all means necessary (1998) (0)
Chapter 22:Impact of Drug Transporters in the Pharmacological and Adverse Reactions of Drugs (2011) (0)
Phase 0/microdosing approaches: time for mainstream application in drug development? (2020) (0)
Self-Position Estimation Technology using Multi Angle VisionTM (2019) (0)
Functional characterization of MRP4 (2004) (0)
2C-22 Quantitative prediction of in vivo metabolic activity in the liver from in vitro data based on the P450 isozyme involved. (1997) (0)
Microsoft Word-8776138-file00 (2009) (0)
A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions (2017) (0)
The low level expression of multidrug resistance 3 P- glycoprotein (MDR3) and phosphatidylcholine-transfer protein (PC-TP) in the liver of patients with intrahepatic calculi - A basic defect for the pathogenesis (2000) (0)
DMD055475 685..694 (2014) (0)
1. Drug Transporters in the New Drug Discovery and Development (2009) (0)
Nonlinear parameter tomography system for breast scanning (1985) (0)
The 8 th and 9 th transmembrane domains in organic anion-transporting polypeptide ( OATP ) 1 B 1 affects the transport kinetics of estrone-3-sulfate and estradiol-17 β-D-glucuronide (2009) (0)
Binding and transport of methotrexate and its derivative, MX‐68, across the brush‐border membrane in rat kidney (1999) (0)
Short-chain Ubiquitination Is Associated with the Degradation Rate of a Cell-surface-resident Bile Salt Export Pump Mol #49288 2 (2008) (0)
Role of transporter sciences in new drug discovery and development. (2020) (0)
SYNTHESIS OF UNSYMMETRIC N,N′-DISUBSTITUTED AMIDINOFORMIC ACIDS (1974) (0)
The Optimization Analysis of Moments in the Combinatorial Model System (1989) (0)
PHARMACOKINETICS WITH CYP 2 D 6 GENOTYPES (2009) (0)
MOUSE RST FACILITATES TRANSCELLULAR TRANSPORT OF ORGANIC ANIONS BY A COORDINATION OF BASOLATERAL ORGANIC ANIO N TRANSPORTERS (OAT3 ) (2004) (0)
DNAMethylation and Histone Modification Profiles of Mouse Organic Anion Transporting Polypeptides s (2012) (0)
Pharmacokinetics of a Granulocyte Colony-stimulating Factor (G-CSF)—Role of Receptor-mediated Clearance in the Disposition of G-CSF— (1996) (0)
A simple decision tree suited for identification of early oral drug candidates with likely pharmacokinetic nonlinearity by intestinal CYP3A saturation. (2020) (0)
Immunohistochemical Study on Distribution and Response of Nerve Fibers in Rat Periodontal Tissue : Comparison of Reinnervation after Gingivectomy with Surgical Knife and Electrotome (1995) (0)
Construction of the in vitro transporter experimental systems for prediction of the dexification of drugs in human liver : Utilization of human cryopreserved hepatocytes and double transfectants (2006) (0)
PREDICTION OF DRUG-DRUG INTERACTION CAUSED BY INTESTINAL CYP3A4 AND P-GP (2008) (0)
The forefront of genome clinical pharmacology. The result that the millennium project brought about. 2. Pharmacodynamics-related gene mutation and clinical pharmacology. (2006) (0)
NONLINEARITY OF HMG-COA REDUCTASE INHIBITOR, PRAVASTATIN IN BOTH HEPATIC UPTAKE AND BILIARY EXCRETION PROCESSES (1995) (0)
KINETIC ANALYSIS OF RENAL TUBULAR TRANSPORT OF CIMETIDINE IN RATS BASED ON MULTIPLE INDICATOR DILUTION STUDIES (1985) (0)
Erratum: Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine (2020) (0)
Kinetic analysis of the transport of the quinolone antibiotics across the blood-brain barrier and blood-CSF barrier (1993) (0)
KINETIC ANALYSIS OF DISPOSITION OF HUMAN EPIDERMAL GROWTH FACTOR (EGF) : ANALYSIS USING FRESHLY ISOLATED RAT HEPATOCYTE AND ANALYSIS OF RECEPTOR DYNAMICS IN ORGANS IN VIVO (1989) (0)
A Novel Drug Delivery System of Hepatocyte Growth Factor (HGF): Utilization of Heparin-HGF Complex (1996) (0)
Effect of pharmaceutical excipients on the function of intestinal xenobiotics efflux transporter, the breast cancer resistance protein (2005) (0)
THE DOWN AND UP-REGULATION OF THE RECEPTOR-MEDIATED ENDOCYTOSIS FOR THE G-CSF DERIVATIVE (1994) (0)
The uptake kinetics of hepatocyte growth factor in perfused rat liver (1992) (0)
Erratum: A Novel Hepatic-Targeting System for Therapeutic Cytokines That Delivers to the Hepatic Asialoglycoprotein Receptor, But Avoids Receptor-Mediated Endocytosis Pharm. Res. 19:1736-1744 (2002) (2004) (0)
Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802 (2016) (0)
The role of breast cancer resistance protein, Bcrp in the transport of estrone-3-sulfate and dehydroepiandrosterone sulfate across the blood-brain barrier (2003) (0)
[Kinetic analysis of hepatic transport of bioactive polypeptides based on receptor-mediated endocytosis: EGF as a model polypeptide]. (1990) (0)
Extrapolation of drug safety assessment to humans : Role of pharmacokinetic studies (1998) (0)
SL 11 Importance of Drug Transporter Studies in the New Drug Discovery and Development (2010) (0)
Professor Margareta Hammarlund-Udenaes - A Humble Scientist Shaping Modern Neuropharmacokinetics (2022) (0)
ADDITION OF METHANESULFENYL CHLORIDE AND SULFUR CHLORIDE TO 1,4‐DIMETHYL‐3,6‐DIMETHYLENE‐2,5‐PIPERAZINEDIONE AND SUBSTITUTION OF THE ADDUCTS (1974) (0)
INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT USING MICRODOSING CLINICAL STUDY (5):IDENTIFICATION OF HUMAN METABOLITES BY A CONBINATORIAL USE OF AMS AND LC/MS/MS (2009) (0)
Role of drug transporter studies in the drug discovery and development (2006) (0)
The drug-drug interactions of clopiodgrel for OATP1B1 and CYP2C8: In vitro prediction and a clinical cassette small-dose study (2017) (0)
General lectures (II) (2007) (0)
Identification of transporters involved in the hepatobiliary transport of PET probe, 15R- [11C]TIC, change in its plasma and hepatic concentration by drug interaction in humans and its prediction from in vitro experiments (2009) (0)
Selective extraction of U(VI) and some other metals from nitric acid media by poly-phosphine poly-oxides (2008) (0)
erythropoietin-induced uptake clearance by the spleen Mechanism of the upregulation of (2005) (0)
[Primary active transporter responsible for the biliary excretion of xenobiotics]. (1997) (0)
POSSIBLE MECHANISMS FOR THE CHANGES IN MICROCLIMATE-pH IN THE RAT SMALL INTESTINE AND EFFECTS OF PHENOTHIAZINE DERIVATIVES IN VIVO (1987) (0)
PHYSIOLOGICAL PHARMACOKINETICS OF TOLBUTAMIDE-SULFONAMIDES INTERACTION IN RATS (1981) (0)
Expression and functional characterization of breast cancer resistance protein (ABCG2) in mouse intestine (2005) (0)
ESTIMATION OF THE RELATIVE CONTRIBUTION OF EFFLUX TRANSPORTERS TO OVERALL BILIARY EXCRETION FROM IN VITRO SANDWICH-CULTURED RAT HEPATOCYTES (2008) (0)
Construction of a physiologically-based pharmacokinetic model of coproporphyrin I, a putative endogenous probe for hepatic OATP1Bs and MRP2 (2018) (0)
Inhibitory effect of quinidine and quinine on the oatp1- and oatp2- mediated transport (1999) (0)
[Preparation of plasma membrane and the analysis of transport kinetics and driving forces]. (1996) (0)
Role of MRP family proteins in the export of organic anion compounds from liver and intestine (1997) (0)
Roles of drug transporters in the adverse reactions of drugs (2013) (0)
INTERACTION OF OUABAIN AND ROSE BENGAL WITH RAT LIVER PLASMA MEMBRANES (1985) (0)
PREDICTION OF THE IN VIVO DRUG METABOLIZING ACTIVITY IN HUMAN LIVER FROM IN VITRO DATA ON METABOLISM : THE USE OF HUMAN LIVER MICROSOMES AND RECOMBINANT HUMAN CYP ISOZYMES (1999) (0)
Regulation of the cell surface expression and transport capacity of bile salt export pump by small chemical molecules (2009) (0)
The molecular expression levels of intracellular carriers and canalicular membrane transporters of cholesterol, phospholipid and bile acid in the liver of patients with intrahepatic calculi, and etiological significance (1999) (0)
Innovative Strategies for drug development using microdosing clinical studies (NEDO MicroDose-PJ) 2010 (2)- Prediction of the role of P-gp and CYP3A4 in the non-linear intestinal absorption of quinidine and verapamil (2010) (0)
QUANTITATIVE RELATIONSHIP BETWEEN IN VIVO BENZODIAZEPINE RECEPTOR OCCUPANCY AND CEREBRAL METABOLIC CHANGE IN THE MOUSE (1990) (0)
Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers (2019) (0)
Professor Akira Tsuji: scientist, educator, and leader. (2011) (0)
EFFECT OF OATP 1 B 1 ( OATP-C / OATP 2 ) * 1 b ON THE PHARMACOKINETICS OF PRAVASTATIN , VALSARTAN AND TEMOCAPRIL IN HEALTHY JAPANESE VOLUNTEERS (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yuichi Sugiyama?

Yuichi Sugiyama is affiliated with the following schools:

Yuichi Sugiyama's Academic­Influence.com Rankings

Yuichi Sugiyama's Degrees

Similar Degrees You Can Earn

Why Is Yuichi Sugiyama Influential?

Yuichi Sugiyama's Published Works

Published Works

What Schools Are Affiliated With Yuichi Sugiyama?

Yuichi Sugiyama's AcademicInfluence.com Rankings